S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:CRNX

Crinetics Pharmaceuticals Earnings Date, Estimates, & History

$19.58
+0.61 (+3.22%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.95
$19.68
50-Day Range
$18.97
$28.41
52-Week Range
$13.83
$28.95
Volume
327,098 shs
Average Volume
240,840 shs
Market Capitalization
$930.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35

Earnings Summary

Upcoming
Earnings Date
Mar. 29
Estimated

Actual EPS
(Nov. 5)
-$0.73
Missed By -$0.01

Consensus EPS
(Nov. 5)
-$0.72

Last Year's Q4 EPS
(11/11/2020)
-$0.56

Skip Charts & View Estimated and Actual Earnings Data

Crinetics Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Crinetics Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.75)($0.72)($0.74)
Q2 20222($0.85)($0.77)($0.81)
Q3 20222($0.95)($0.82)($0.89)
Q4 20222($1.35)($0.87)($1.11)
FY 20228($3.90)($3.18)($3.54)

CRNX Earnings Information

Crinetics Pharmaceuticals last announced its quarterly earnings data on November 5th, 2021. The reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.01. Crinetics Pharmaceuticals has generated ($2.78) earnings per share over the last year (($2.78) diluted earnings per share). Earnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($2.71) to ($2.54) per share. Crinetics Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 29th, 2022 based off prior year's report dates.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
3/29/2022
(Estimated)
        
11/5/20219/30/2021($0.72)($0.73)($0.01)($0.73)    
8/9/20216/30/2021($0.61)($0.70)($0.09)($0.70)
5/6/20213/31/2021($0.66)($0.69)($0.03)($0.69)  
3/29/202112/31/2020($0.58)($0.66)($0.08)($0.66)  
11/11/20209/30/2020($0.53)($0.56)($0.03)($0.56)  
8/7/20206/30/2020($0.55)($0.53)+$0.02($0.53)
5/8/20203/31/2020($0.63)($0.71)($0.08)($0.71)$0.07 million
3/9/202012/31/2019($0.68)($0.60)+$0.08($0.60)$0.30 million$0.32 million
11/12/2019Q3 2019($0.5680)($0.60)($0.0320)($0.60)$0.33 million$0.51 million
8/13/2019Q2 2019($0.4560)($0.51)($0.0540)($0.51)$0.33 million
5/13/2019Q1($0.41)($0.37)+$0.04($0.37)$0.25 million$0.37 million
3/13/2019Q4($0.4120)($0.35)+$0.0620($0.35)$0.32 million$0.78 million
11/13/2018Q3 2018($0.3430)($0.38)($0.0370)($0.38)$0.28 million$0.55 million
8/30/2018Q2 2018($0.2870)($2.41)($2.1230)($2.41)$0.09 million$0.66 million
(Earnings results data provided by Zacks Investment Research)












Crinetics Pharmaceuticals (NASDAQ:CRNX) Earnings Frequently Asked Questions

When is Crinetics Pharmaceuticals's earnings date?

Crinetics Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 29th, 2022 based off last year's report dates. Learn more on CRNX's earnings history

Did Crinetics Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Crinetics Pharmaceuticals (NASDAQ:CRNX) missed the analysts' consensus estimate of ($0.72) by $0.01 with a reported earnings per share (EPS) of ($0.73). Learn more on CRNX's earnings details

How can I listen to Crinetics Pharmaceuticals's earnings conference call?

The conference call for Crinetics Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Crinetics Pharmaceuticals's conference call transcript?

The conference call transcript for Crinetics Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Crinetics Pharmaceuticals generate each year?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded annual revenue of $70 thousand.

How much profit does Crinetics Pharmaceuticals generate each year?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded net income of -$73.81 million. CRNX has generated -$2.78 earnings per share over the last four quarters.

What is Crinetics Pharmaceuticals's EPS forecast for next year?

Crinetics Pharmaceuticals's earnings are expected to grow from ($2.71) per share to ($2.54) per share in the next year.

This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.